FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
ACE-031 is a recombinant fusion protein built to act as a soluble decoy receptor for a specific set of signaling molecules in the transforming growth factor beta (TGF-beta) superfamily. Rather than a small peptide, it is a large glycosylated protein that pairs the ligand-binding portion of the activin receptor type IIB with an antibody fragment, and its research value comes from a single, well-defined function: it intercepts ligands such as myostatin before they can reach their cell-surface receptor. This article describes the activin receptor type IIB and its ligands, how ACE-031 works as a decoy receptor, its ligand specificity within the myostatin pathway, and the preclinical skeletal muscle research it has been used in.
Research Snapshot
- ACE-031 is a recombinant fusion protein composed of the extracellular ligand-binding domain of the activin receptor type IIB (ActRIIB) joined to the Fc region of human immunoglobulin G1 (IgG1). It is a glycosylated homodimer of approximately 80 kDa, not a peptide.
- It functions as a soluble decoy receptor, or ligand trap. By binding TGF-beta superfamily ligands in the extracellular space, it prevents them from engaging the membrane-bound receptor and activating downstream SMAD2/3 signaling (Lee et al., 2005).
- Its principal ligands include myostatin (GDF-8) and GDF-11, along with activin A, activin B, and, to a degree, BMP-9. This broad specificity distinguishes it from single-ligand inhibitors.
- Myostatin is a negative regulator of skeletal muscle mass, so a decoy that sequesters myostatin has been used in preclinical research as a tool for studying muscle regulation (Lee and McPherron, 2001), including a study reporting increased muscle mass in a non-human primate model.
- Pure Health Peptides supplies ACE-031 as a lyophilized Vial (1 mg), as a research-grade reagent characterized per lot. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
Introduction
ACE-031 sits at the intersection of receptor biology and protein engineering. The activin receptor type IIB is a cell-surface receptor that a number of TGF-beta superfamily ligands signal through, and several of those ligands, myostatin foremost among them, act to restrain skeletal muscle growth. ACE-031 was engineered to exploit that biology in reverse: by taking the part of the receptor that binds those ligands and making it soluble, it becomes a trap that pulls the ligands out of circulation before they can signal.
This article treats ACE-031 as a research tool and stays with its mechanism. It describes the receptor and the ligands it engages, the decoy-receptor design that defines the molecule, the breadth of its ligand specificity, and the preclinical skeletal muscle research in which it has been used. Because ACE-031 is a recombinant protein rather than a synthetic peptide, and because Pure Health Peptides supplies it strictly as a research-grade reagent, the appropriate frame throughout is molecular and preclinical.
The Activin Receptor Type IIB and Its Ligands
The activin receptor type IIB, abbreviated ActRIIB, is a type II receptor in the TGF-beta superfamily signaling system. Type II receptors of this family bind their ligands and then recruit type I receptors to form a signaling complex, which activates the intracellular SMAD proteins that carry the signal to the nucleus. ActRIIB is notable because a range of ligands converge on it, including myostatin (also called GDF-8), the closely related GDF-11, and the activins.
Myostatin is the ligand that gives this receptor system much of its research prominence. It functions as a negative regulator of skeletal muscle mass, restraining muscle growth through ActRIIB and the downstream SMAD2/3 pathway. Foundational work established that reducing myostatin activity is associated with increased skeletal muscle in animal models (Lee and McPherron, 2001), which made the ligands that signal through ActRIIB, and the receptor itself, a focus for research into how muscle mass is controlled.
ACE-031 as a Soluble Decoy Receptor
The design of ACE-031 follows directly from that receptor biology. The molecule takes the extracellular, ligand-binding domain of ActRIIB, the part of the receptor that would normally sit on the cell surface and capture ligands, and fuses it to the Fc region of human IgG1. The Fc portion provides stability and turns the construct into a soluble, dimeric protein that circulates rather than sitting in a membrane.
The result is a decoy receptor. Because the soluble ActRIIB domain binds the same ligands as the membrane receptor, it competes for them in the extracellular space, sequestering ligands such as myostatin before they can engage cell-surface ActRIIB. With the ligands trapped, the downstream SMAD2/3 signaling that would ordinarily restrain muscle mass is reduced. This ligand-trap strategy, using a soluble form of a type II receptor to neutralize multiple ligands at once, was characterized in research on activin type II receptor signaling and muscle growth (Lee et al., 2005), and ACE-031 is one of the defined molecular tools built on that principle.
Ligand Specificity and the Myostatin Pathway
A defining feature of ACE-031 is the breadth of what it binds. The ActRIIB extracellular domain does not recognize myostatin alone. Its ligand specificity extends across several TGF-beta superfamily members, including GDF-8 (myostatin), GDF-11, activin A, activin B, and, to a degree, BMP-9. That breadth is the central research consideration when working with ACE-031, because it means the molecule cannot be treated as a clean single-target myostatin inhibitor.
This distinguishes it from more selective approaches to the same pathway. A follistatin-derived fragment, for example, also antagonizes myostatin and activin, but the receptor-trap architecture of ACE-031 casts a wider net across the ligand set. For a researcher, that difference is the point: comparing a broad decoy receptor like ACE-031 against a more selective antagonist is a way to dissect which effects in a model depend on which ligands. The Follistatin 315 research covers the more selective side of that same pathway, and the two make a natural pair for comparative work.
Preclinical Skeletal Muscle Research
The research use of ACE-031 follows from its mechanism. Because it lowers signaling from myostatin and related ligands, and because that signaling restrains muscle, ACE-031 has been used in preclinical models as a tool for probing the myostatin pathway and its role in the regulation of muscle mass. Its multi-ligand reach tends to produce a larger effect on muscle in these models than a single-ligand inhibitor, which is one reason it became a widely used experimental probe of the pathway.
That research extends into higher animal models. A study in the common marmoset, a non-human primate, reported that ACE-031 increased muscle mass and strength, extending the myostatin-pathway findings beyond rodents into a primate system. Across this work, the framing is preclinical and mechanistic. ACE-031 is a molecular tool for interrogating the physiological roles of myostatin and its related ligands in muscle homeostasis and related systems, and its value in research rests on that pathway biology rather than on any applied outcome. This growth-and-repair pathway is part of the broader research theme covered in the cellular repair and regeneration overview.
Format, Handling, and Verification
ACE-031 is supplied in a single carrier format, a lyophilized Vial at 1 mg, as a research-grade reagent. Because it is a recombinant glycoprotein of approximately 80 kDa rather than a small molecule, it does not carry a discrete molecular formula and is characterized per lot by analytical methods appropriate to proteins, such as SDS-PAGE and size-exclusion chromatography, with the specification reported on the lot-specific Certificate of Analysis. As the product documentation states, it is a research-grade reagent, not manufactured under GMP conditions and not equivalent to or a substitute for any clinical or pharmaceutical-grade material, supplied strictly for controlled in vitro laboratory research.
Underneath the format is the verification chain. Pure Health Peptides does not manufacture the material; production is sourced from qualified third-party manufacturers, and the material is finished and tested domestically, as described on the Manufacturing Process page. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner, and each qualified lot’s Certificate of Analysis is published in the COA Library, in the vial section, retrievable by batch ID. For a lyophilized vialed biologic, the appropriate panel extends beyond identity and purity to include endotoxin and microbial limits, because contamination can enter downstream of production through handling, lyophilization, vial filling, storage, and transit. The Testing Process page documents how that verification runs, and the same standard applies to every product in the Pure Health Peptides catalog.
Where ACE-031 Sits in Myostatin-Pathway Research
For researchers studying the control of skeletal muscle mass, ACE-031 is a defined molecular tool with a distinctive profile: a soluble receptor domain that traps a whole set of TGF-beta superfamily ligands rather than a single one. Its research value rests on that breadth and on the receptor biology behind it. It is the wide-net counterpart to more selective antagonists of the same pathway, and the contrast between the two is itself a research question. As work on myostatin, GDF-11, and the activins continues, decoy receptors like ACE-031 remain central tools for asking what each ligand contributes, and the molecule holds a specific place in that toolkit as the broad-specificity ActRIIB trap.
Frequently Asked Questions
What is ACE-031?
ACE-031 is a recombinant fusion protein made of the extracellular ligand-binding domain of the activin receptor type IIB (ActRIIB) fused to a human IgG1 Fc region. It is a glycosylated homodimer of approximately 80 kDa and functions as a soluble decoy receptor.
Is ACE-031 a peptide?
No. It is a large recombinant fusion protein produced in mammalian cell systems, not a synthetic peptide. It is characterized per lot by protein methods rather than by a small-molecule formula.
How does ACE-031 work as a ligand trap?
The soluble ActRIIB domain binds TGF-beta superfamily ligands, including myostatin (GDF-8), GDF-11, and the activins, in the extracellular space, preventing them from engaging the cell-surface receptor and reducing the downstream SMAD2/3 signaling those ligands would otherwise drive.
Why is ACE-031 studied in skeletal muscle research?
Because myostatin is a negative regulator of skeletal muscle mass, and ACE-031 sequesters myostatin along with related ligands. In preclinical models it has been used as a tool to study the myostatin pathway and the regulation of muscle mass.
What carrier format is ACE-031 available in, and how is it verified?
A lyophilized vial (1 mg), as a research-grade reagent. Every lot is routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, characterized by protein-appropriate methods, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Lee SJ, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences, 2005;102(50):18117-18122.
- Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proceedings of the National Academy of Sciences, 2001;98(16):9306-9311.
- ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PLOS One.
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories.
